Onyx continues to be driven by Nexavar

By Lisa Kerner

Charlotte, N.C., Oct. 18 - Nexavar (sorafenib), the oral antiangiogenic/ antiproliferation product for the treatment of cancer from Onyx Pharmaceuticals, Inc., continues to be a strong driver, company officials said Wednesday.

"We're building a business around Nexavar with nearly global approval of the drug," chairman and chief executive officer Hollings C. Renton said at the 2006 BIO Investor Forum conference in San Francisco.

"Not only is it on the market, but we've completed accruals in two additional pivotal studies and many others are underway. Nexavar is clearly our foundation for growth in the oncology market."

Renton highlighted Nexavar's first-half 2006 net sales of $55.9 million, attributed to the company's co-development partner, Bayer Pharmaceuticals Corp. Onyx said it will continue to leverage Bayer's capabilities moving forward.

Onyx is an Emeryville, Calif., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.